Relationship between growth velocity and change of levels of insulin-like growth factor-1, insulin-like growth factor binding protein-3 and, IGFBP-3 promoter polymorphism during GnRH agonist treatment

키워드

참고문헌 (28)

1. Kliegman RM, "Nelson textbook of pediatrics", pp.2899~2912 (2019), Elsevier Saunders
2. Kim YJ, "Incidence and prevalence of central precocious puberty in Korea : an epidemiologic study based on a national database", J Pediatr, 208, pp.221~228 (2019)
3. Carel JC, "Precocious puberty and statural growth", Hum Reprod Update, 10, pp.135~147 (2004)
4. Adan L, "Factors predicting adult height in girls with idiopathic central precocious puberty : implications for treatment", Clin Endocrinol, 56, pp.297~302 (2002)
5. Attie KM, "The pubertal growth spurt in eight patients with true precocious puberty and growth hormone deficiency:evidence for a direct role of sex steroids", J Clin Endocrinol Metab, 71, pp.975~983 (1990)
6. Paul D, "Long-term effect of gonadotropin-releasing hormone agonist therapy on final and near-final height in 26 children with true precocious puberty treated at a median age of less than 5years", J Clin Endocrinol Metab, 80, pp.546~551 (1995)
7. Allali S, "Predicting the adult height of girls with central precocious puberty", Med Sci Monit, 17, pp.PH41~PH48 (2011)
8. Kauli R, "Final height of girls with central precocious puberty, untreated versus treated with cyproterone acetate or GnRH analogue. A comparative study with re-evaluation of predictions by the Bayley-Pinneau method", Horm Res, 47, pp.54~61 (1997)
9. Antoniazzi F, "Bone mineral metabolism in girls with precocious puberty during gonadotrophinreleasing hormone agonist treatment", Eur J Endocrinol, 133, pp.412~417 (1995)
10. Costalonga EF, "The -202 A allele of insulinlike growth factor binding protein-3 (IGFBP3) promoter polymorphism is associated with higher IGFBP-3 serum levels and better growth response to growth hormone treatment in patients with severe growth hormone deficiency", J Clin Endocrinol Metab, 94, pp.588~595 (2009)
11. Costalonga EF, "Growth hormone pharmacogenetics : the interactive effect of a microsatellite in the IGF1 promoter region with the GHR-exon 3 and-202 A", C IGFBP3 variants on treatment outcomes of children with severe GH deficiency, 2012, pp.12, 439~445
12. 이민주, "Influence of The -202 A", C insulin-like growth factorbinding protein-3 promoter polymorphism on individual variation in height in Korean girl, 2017, pp.22(1), 36~42[DOI]
13. Greulich WW, "Radiographic atlas of skeletal development of the hand and wrist", pp.256~ (1959), Stanford University Press
14. Deal C, "Novel promoter polymorphism in insulin-like growth factor-binding protein-3 : correlation with serum levels and interaction with known regulators", J Clin Endocrinol Metab, 86, pp.1274~1280 (2001)
15. Cole TJ, "The LMS method for constructing normalized growth standards", Eur J Clin Nutr, 44, pp.45~60 (1990)
16. 문진수, "2007 한국 소아 청소년 성장도표 : 개발 과정과 전망", Clinical and Experimental Pediatrics, 51(1), pp.1~25 (2008), 대한소아청소년과학회
17. Hyun SE, "Reference values for serum levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3in Korean children and adolescents", Clin Biochem, 45, pp.16~21 (2012)
18. Juul A, "Serum concentrations of free and total insulin-like growth factor-I, IGF binding proteins -1 and -3 and IGFBP-3protease activity in boys with normal or precocious puberty", Clin Endocrinol, 44, pp.515~523 (1996)
19. Verrotti A, "Serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 levels in children with precocious puberty treated with gonadotropin-releasing hormone analog without or in combination with cyproterone acetate", Gynecol Endocrinol, 11, pp.243~250 (1997)
20. Kanety H, "Insulinlike growth factor-I and IGF binding protein-3 remain high after GnRH analogue therapy in girls with central precocious puberty", Clin Endocrinol, 45, pp.7~12 (1996)
21. Sklar CA, "Suppression of the pituitary-gonadal axis in children with central precocious puberty: effects on growth, growth hormone, insulin-like growth factor-I, and prolactin secretion", J Clin Endocrinol Metab, 73, pp.734~738 (1991)
22. Cisternino M, "The acid-labile subunit of human ternary insulin-like growth factor-binding protein complex in girls with central precocious puberty before and during gonadotropin-releasing hormone analog therapy", J Clin Endocrinol Metab, 87, pp.4629~4633 (2002)
23. 송한솔, "Relationship between serum insulin-like growth factor-1, IGF binding protein-3 levels and body height before and after gonadotropin-releasing hormone agonist therapy", Annals of Pediatric Endocrinology & Metabolism, 19(4), pp.208~213 (2014), 대한소아내분비학회
24. van der Kaay DC, "Genetic and epigenetic variability in the gene for IGFBP-3 (IGFBP3): correlation with serum IGFBP-3 levels and growth in short children born small for gestational age", Growth Horm IGF Res, 19, pp.198~205 (2009)
25. Park K, "Influence of IGFBP3 gene polymorphisms on IGFBP3 serum levels and the risk of prostate cancer in low-risk Korean men", Urology, 75, pp.1516.e1~1516.e7 (2010)
26. Safarinejad MR, "Relationship of insulin-like growth factor (IGF) binding protein-3(IGFBP-3) gene polymorphism with the susceptibility to development of prostate cancer and influence on serum levels of IGF-I, and IGFBP-3", Growth Horm IGF Res, 21, pp.146~154 (2011)
27. Miletta MC, "Association of the (CA)n repeat polymorphism of insulin-like growth factor-I and -202A", C IGF-binding protein-3 promoter polymorphism with adult height in patients with severe growth hormone deficiency, 2012, pp.76, 683~690
28. Han SG, "Single nucleotide polymorphisms of IGFBP-3 gene and lung cancer risk in a Korean population", Lung Cancer, 62, pp.152~161 (2008)

관련 논문AI추천